Latest News

Phase 3 Neo-Healer shows anbenitamab plus HB1801 boosts complete response rates in ERBB2-positive breast cancer, with manageable safety.

The study also identified a link between early fatigue and eventual response to CAR-T.

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

Etentamig surpassed standard therapy in terms of response rate and progression-free survival in the phase 3 CERVINO trial for relapsed/refractory multiple myeloma.

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

Daraxonrasib showed dose-dependent objective response rates of 31% to 37% in previously treated RAS-mutant NSCLC, per phase 1/2 trial data published in the New England Journal of Medicine.

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

Phase 3 SANOVO shows savolitinib plus osimertinib extends PFS in first-line EGFR-mutant, MET-high NSCLC, hinting at OS gains.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and AI-powered documentation.

The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer.

FDA aligns on IDE849 phase 3 trial in post-tarlatamab ES-SCLC, testing DLL3 ADC vs chemo, aiming for accelerated approval.

August 2026 FDA oncology updates: iberdomide, zanidatamab, and daraxonrasib win approvals as fast-track designations accelerate targeted pipelines.

A JAK inhibitor with a favorable safety profile demonstrated clinical activity in patients with chronic graft-vs-host disease.

The approval marks the first new agent specifically approved for essential thrombocythemia in the US in nearly 30 years.

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography rather than one-size-fits-all follow-up.

The approval is primarily supported by the phase 3 VERIFY study.

Almost one-third of patients became newly eligible for treatment after identification of a previously undetected druggable mutation.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk assessment for polycythemia vera.

Shubham Pant, MD, MBBS, explains the significance of the FDA approval of daraxonrasib for mPDAC.

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor payload.

Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2– metastatic breast cancer, after VIKTORIA-1 shows longer PFS than alpelisib.

ERAS-0015 is being tested in AURORAS-1, an open-label study enrolling patients with RAS-mutant solid tumors.

The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.

The LRRC15-targeting antibody-drug conjugate will be investigated in a first-in-human trial later this year.

The final recommendations were directly shaped by data from 36 published articles.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.